Literature DB >> 11181840

Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs.

L Dazzi1, F Spiga, L Pira, S Ladu, G Vacca, A Rivano, J D Jentsch, G Biggio.   

Abstract

The effects of long-term treatment with imipramine or mirtazapine, two antidepressant drugs with different mechanisms of action, on the response of cortical dopaminergic neurons to foot-shock stress or to the anxiogenic drug FG7142 were evaluated in freely moving rats. As expected, foot shock induced a marked increase (+ 90%) in the extracellular concentration of dopamine in the prefrontal cortex of control rats. Chronic treatment with imipramine or mirtazapine inhibited or prevented, respectively, the effect of foot-shock stress on cortical dopamine output. Whereas acute administration of the anxiogenic drug FG7142 induced a significant increase (+ 60%) in cortical dopamine output in control rats, chronic treatment with imipramine or mirtazapine completely inhibited this effect. In contrast, the administration of a single dose of either antidepressant 40 min before foot shock, had no effect on the response of the cortical dopaminergic innervation to stress. These results show that long-term treatment with imipramine or mirtazapine inhibits the neurochemical changes elicited by stress or an anxiogenic drug with an efficacy similar to that of acute treatment with benzodiazepines. Given that episodes of anxiety or depression are often preceded by stressful events, modulation by antidepressants of the dopaminergic response to stress might be related to the anxiolytic and antidepressant effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181840     DOI: 10.1046/j.1471-4159.2001.00148.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex.

Authors:  Wei Si; Leah Aluisio; Naoe Okamura; Stewart D Clark; Ian Fraser; Steven W Sutton; Pascal Bonaventure; Rainer K Reinscheid
Journal:  J Neurochem       Date:  2010-08-30       Impact factor: 5.372

2.  Cortical 3 alpha-hydroxy-5 alpha-pregnan-20-one levels after acute administration of Delta 9-tetrahydrocannabinol, cocaine and morphine.

Authors:  A Chistina Grobin; Margaret J VanDoren; Linda J Porrino; A Leslie Morrow
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

3.  Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia.

Authors:  Christoph U Correll; Christopher W Smith; Andrea M Auther; Danielle McLaughlin; Manoj Shah; Carmel Foley; Ruth Olsen; Todd Lencz; John M Kane; Barbara A Cornblatt
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-10       Impact factor: 2.576

Review 4.  Ventral tegmental area dopamine revisited: effects of acute and repeated stress.

Authors:  Elizabeth N Holly; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2015-12-17       Impact factor: 4.530

5.  Long-term behavioral consequences of prenatal MDMA exposure.

Authors:  Valerie B Thompson; Justin Heiman; James B Chambers; Stephen C Benoit; William R Buesing; Mantana K Norman; Andrew B Norman; Jack W Lipton
Journal:  Physiol Behav       Date:  2008-12-31

6.  Behavioral and Biochemical Interaction Between Nicotine and Chronic Unpredictable Mild Stress in Mice.

Authors:  G Biala; K Pekala; A Boguszewska-Czubara; A Michalak; M Kruk-Slomka; B Budzynska
Journal:  Mol Neurobiol       Date:  2016-01-18       Impact factor: 5.590

7.  Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.

Authors:  Naoto Kadoguchi; Shinji Okabe; Yukio Yamamura; Misaki Shono; Tatsuya Fukano; Akie Tanabe; Hironori Yokoyama; Jiro Kasahara
Journal:  BMC Neurosci       Date:  2014-06-25       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.